Nautilus Biotechnolgy, Inc. (NAUT) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nautilus Biotechnology, Inc. faces a significant risk of its Common Stock being delisted from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. This situation could adversely affect the company’s ability to sell equity securities and the liquidity of its stock. Despite efforts to transfer its listing to the Nasdaq Capital Market and potentially conduct a reverse stock split, there is no assurance of regaining compliance. Delisting could lead to reduced market quotations, liquidity, and trading activity, as well as hinder future financing opportunities.
Overall, Wall Street has a Moderate Buy consensus rating on NAUT stock based on 2 Buys.
To learn more about Nautilus Biotechnolgy, Inc.’s risk factors, click here.